Skip to main content

Table 1 Nomination of candidate PARPi combination therapies based on identified molecular processes and existing small molecular drugs with clinical relevance

From: Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

Molecular process

Target

Drug combination with PARPi

Lipid metabolism

FASN

PARPi + TVB-2640

NF-κB signaling

IκBα

PARPi + Bortezomib

Cell proliferation

ElF5A-2

PARPi + N(1)-guanyl-1,7,-diamineohephane (GC7)

Mitotic exit

UBE2S/APC/C

PARPi + proTAME